Cleft Lip PalatePhase 3NCT07305623
Safety and Efficacy of Bone Bioengineering Kit With Stem Cells for Alveolar Cleft Repair
A Phase 3 study testing Bioengineering kit composed of stem cells from deciduous teeth and biomaterial. and iliac crest bone graft surgery in people with Cleft Lip Palate, run by Instituto de Tecnologia do Paraná at 2 sites in Brazil.
Trial summary
The objective of this study is to compare the safety and efficacy of a bone tissue engineering kit - composed of 10⁶ autologous mesenchymal stem cells derived from deciduous dental pulp combined with Bio-Oss® Collagen - with secondary autogenous iliac crest bone grafting for alveolar cleft reconstruction in patients… Read more about this study
- Who is it for?
- Ages 7 to 12 years
- Conditions the study is for
- Cleft Lip Palate
- What is being tested?
- Bioengineering kit composed of stem cells from deciduous teeth and biomaterial. and iliac crest bone graft surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 205 participants
- Where
- 2 sitesBrazil
- Study dates
- Jul 2026to Dec 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Written Informed Consent Form (ICF) signed by the participant's legally authorized representative.
- Written Assent Form signed by the participant.
- Patients aged 7 to 12 years at the time of secondary alveolar bone graft surgery.
- Patients diagnosed with unilateral pre-foramen or transforamen cleft lip and palate.
- Availability of autologous mesenchymal stem cells derived from deciduous dental pulp, previously stored in a biobank before signing the Informed Consent Form (ICF).
- Patients with a maxillary arch previously aligned through orthodontic treatment and considered suitable for alveolar bone grafting.
Show all 9Show fewer
- Medically fit to undergo the surgical procedure, as determined by the responsible clinical team.
- Complete and up-to-date vaccination schedule according to the Brazilian National Immunization Program (PNI).
- Participants and their legal representatives are considered reliable, willing to comply with the study procedures, attend all required study visits, and remain available throughout the study period.
Who cannot join
- Previous surgery for alveolar cleft repair.
- Known allergy to latex gloves or suture materials (Catgut, Vicryl, Monocryl, Nylon, Polyester, or Polypropylene).
- Uncontrolled systemic diseases or other clinical conditions that may increase surgical risk or interfere with bone healing, including, but not limited to, uncontrolled diabetes mellitus, clinically significant cardiovascular disease, or other conditions deemed relevant by the investigator.
- Metabolic bone diseases or other conditions that may impair bone formation or healing.
- Congenital or acquired immunosuppression, or use of immunosuppressive medications that may interfere with healing or treatment response.
- History of radiotherapy or chemotherapy involving the head and neck region, when applicable, or any other condition that may compromise bone repair.
Show all 14Show fewer
- Presence of palatal fistulas resulting from previous surgeries.
- Incomplete orthodontic or computed tomography documentation.
- Eruption of the permanent canine before signing the Informed Consent Form (ICF) and Assent Form, and before secondary alveolar bone graft surgery.
- Participants who are pregnant or breastfeeding at the time of screening or during the study.
- Presence of systemic infection, active infection of the oral cavity or surgical site, or any infectious condition that, in the investigator's opinion, may compromise participant safety or the study outcomes.
- Inability to obtain or release the investigational product due to failure in cell processing or failure to meet the established quality control criteria.
- Concurrent participation in another interventional clinical trial or previous participation in a study that, in the investigator's judgment, may interfere with the results of the present study.
- Any other condition that, in the opinion of the investigator or designee, may preclude informed consent, pose an unacceptable risk to the participant, compromise protocol compliance, interfere with endpoint assessment, or otherwise jeopardize the objectives of the study.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil2 sites
Hospital Infantil Dr. Jeser Amarante Faria
Joinville, Santa Catarina
Gustavo Lara Achôa, DDS, +55 (47) 3145-1600, gustavo.achoa@unisociesc.com.br
Gustavo Lara Achôa, DDS
Hospitais Universitários da Universidade Estadual de Ponta Grossa (HU-UEPG)
Ponta Grossa, Paraná
Fábio André dos Santos, DDS, +55 (42) 3219-8888, fasantos@uepg.br
Fábio André dos Santos, DDS
About this study
Official title: Phase III Randomized Clinical Trial on the Use of a Bone Bioengineering Kit With Stem Cells Versus Autogenous Iliac Crest Graft for Alveolar Cleft Repair in Patients With Cleft Lip and Palate
The objective of this study is to compare the safety and efficacy of a bone tissue engineering kit - composed of 10⁶ autologous mesenchymal stem cells derived from deciduous dental pulp combined with Bio-Oss® Collagen - with secondary autogenous iliac crest bone grafting for alveolar cleft reconstruction in patients with cleft lip and palate.
Individuals aged 7 to 12 years with unilateral pre-foramen or transforamen cleft lip and palate who require secondary alveolar bone grafting and have previously cryopreserved autologous deciduous dental pulp-derived mesenchymal stem cells will be eligible for inclusion.
The study will be conducted in two stages. Stage 1 is a prospective, single-arm study designed to evaluate the initial safety of the investigational product, with primary endpoints consisting of the incidence of procedure-related adverse events and postoperative pain until hospital discharge. Stage 2 is a prospective, randomized, assessor-blinded clinical trial comparing the bone tissue engineering kit with standard autogenous iliac crest bone grafting. The co-primary endpoints are the success rate of alveolar reconstruction, defined as ≥70% bone fill of the alveolar cleft measured by volumetric computed tomography 12 months after surgery, and the incidence of procedure-related adverse events.
- Conditions
- Cleft Lip Palate
- Being tested
- Bioengineering kit composed of stem cells from deciduous teeth and biomaterial., iliac crest bone graft surgery
- Keywords
- bioengineering kit, Stem cells
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bioengineering kit composed of stem cells from deciduous teeth and biomaterial.Combination product
Bone tissue engineering kit composed of 10⁶ mesenchymal stromal cells/mesenchymal stem cells (MSCs) derived from dental pulp, combined with a biomaterial consisting of hydroxyapatite and collagen (BioOss Collagen, 250 mg, Geistlich).
iliac crest bone graft surgeryProcedure or surgery
standard iliac crest bone graft surgery
| Study group | Role | What they receive |
|---|---|---|
| bioengineering kit | Experimental | Patients will receive the bioengineering kit composed of stem cells from deciduous teeth and biomaterial. Receives: Combination Product: Bioengineering kit composed of stem cells from deciduous teeth and biomaterial. |
| Iliac crest bone graft | Active comparator | Standard iliac crest bone graft surgery Receives: Procedure: iliac crest bone graft surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Success rate of cleft lip and palate alveolar reconstruction surgery
Proportion of participants achieving successful alveolar reconstruction, defined as ≥70% filling of the alveolar cleft with newly formed bone, assessed by volumetric analysis of computed tomography scans.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2025
- Study startJul 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cleft Lip PalateStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients will receive the bioengineering kit composed of stem cells from deciduous teeth and biomaterial.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 205 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Instituto de Tecnologia do Paraná
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniela Franco Bueno, Instituto de Tecnologia do Paraná
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07305623
- Sponsor's protocol ID
- TECPAR_2025
- Status last verified
- Jul 2026
- First submitted
- 12 Dec 2025
- Last updated
- 10 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III Randomized Clinical Trial on the Use of a Bone Bioengineering Kit With Stem Cells Versus Autogenous Iliac Crest Graft for Alveolar Cleft Repair in Patients With Cleft Lip and Palate
- ClinicalTrials.gov ID
- NCT07305623
- Acronym / sponsor ID
- TECPAR_2025
- Conditions
- Cleft Lip Palate
- Keywords
- bioengineering kit, Stem cells
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 205 participants (estimated)
- Lead sponsor
- Instituto de Tecnologia do ParanáUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 26 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to compare the safety and efficacy of a bone tissue engineering kit - composed of 10⁶ autologous mesenchymal stem cells derived from deciduous dental pulp combined with Bio-Oss® Collagen - with secondary autogenous iliac crest bone grafting for alveolar cleft reconstruction in patients with cleft lip and palate.
Individuals aged 7 to 12 years with unilateral pre-foramen or transforamen cleft lip and palate who require secondary alveolar bone grafting and have previously cryopreserved autologous deciduous dental pulp-derived mesenchymal stem cells will be eligible for inclusion.
The study will be conducted in two stages. Stage 1 is a prospective, single-arm study designed to evaluate the initial safety of the investigational product, with primary endpoints consisting of the incidence of procedure-related adverse events and postoperative pain until hospital discharge. Stage 2 is a prospective, randomized, assessor-blinded clinical trial comparing the bone tissue engineering kit with standard autogenous iliac crest bone grafting. The co-primary endpoints are the success rate of alveolar reconstruction, defined as ≥70% bone fill of the alveolar cleft measured by volumetric computed tomography 12 months after surgery, and the incidence of procedure-related adverse events.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Patients will receive the bioengineering kit composed of stem cells from deciduous teeth and biomaterial.
| Arm | Type | Receives |
|---|---|---|
| bioengineering kit | Experimental | Combination Product: Bioengineering kit composed of stem cells from deciduous teeth and biomaterial.Patients will receive the bioengineering kit composed of stem cells from deciduous teeth and biomaterial. |
| Iliac crest bone graft | Active comparator | Procedure: iliac crest bone graft surgeryStandard iliac crest bone graft surgery |
Who may qualify
- Ages
- 7 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (9 listed)
- Written Informed Consent Form (ICF) signed by the participant's legally authorized representative.
- Written Assent Form signed by the participant.
- Patients aged 7 to 12 years at the time of secondary alveolar bone graft surgery.
- Patients diagnosed with unilateral pre-foramen or transforamen cleft lip and palate.
- Availability of autologous mesenchymal stem cells derived from deciduous dental pulp, previously stored in a biobank before signing the Informed Consent Form (ICF).
Key exclusion criteria (14 listed)
- Previous surgery for alveolar cleft repair.
- Known allergy to latex gloves or suture materials (Catgut, Vicryl, Monocryl, Nylon, Polyester, or Polypropylene).
- Uncontrolled systemic diseases or other clinical conditions that may increase surgical risk or interfere with bone healing, including, but not limited to, uncontrolled diabetes mellitus, clinically significant cardiovascular disease, or other conditions deemed relevant by the investigator.
- Metabolic bone diseases or other conditions that may impair bone formation or healing.
- Congenital or acquired immunosuppression, or use of immunosuppressive medications that may interfere with healing or treatment response.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bioengineering kit composed of stem cells from deciduous teeth and biomaterial.Bone tissue engineering kit composed of 10⁶ mesenchymal stromal cells/mesenchymal stem cells (MSCs) derived from dental pulp, combined with a biomaterial consisting of hydroxyapatite and collagen (BioOss Collagen, 250 mg, Geistlich). | Combination product | bioengineering kit |
| iliac crest bone graft surgerystandard iliac crest bone graft surgery | Procedure or surgery | Iliac crest bone graft |
Primary outcome
Success rate of cleft lip and palate alveolar reconstruction surgery
Time frame: 12 months
Proportion of participants achieving successful alveolar reconstruction, defined as ≥70% filling of the alveolar cleft with newly formed bone, assessed by volumetric analysis of computed tomography scans.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Cleft Lip Palate
Not yet recruiting
Comparative Study of Regional Nerve Blocks in Primary Cleft Palate Repair
Cleft Lip, Cleft Palate +/- Lip
Not yet recruiting
Quadratus Lumborum Block for Iliac Bone Harvest in Pediatric Cleft Alveolus Repair
Cleft Lip Palate
RecruitingObservational study
Perceptions of High and Low Intensity Speech Intervention in Children With a Cleft Palate
Cleft Lip and Palate, Cleft Palate Children
Enrolling by invitation
Speech Intervention Frameworks in Cantonese-speaking Children and Adolescences With Cleft Palate +/- Lip
Cleft Palate +/- Lip
Not yet recruitingObservational study
Cleft Lip and Palate Treatment Outcomes Study
Cleft Lip and Palate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hospitais Universitários da Universidade Estadual de Ponta Grossa (HU-UEPG)
Ponta Grossa, Brazil
Hospital Infantil Dr. Jeser Amarante Faria
Joinville, Brazil
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bioengineering kit composed of stem cells from deciduous teeth and biomaterial. and iliac crest bone graft surgery in people with Cleft Lip Palate, run by Instituto de Tecnologia do Paraná at 2 sites in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Success rate of cleft lip and palate alveolar reconstruction surgery (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jul 2026.